Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acetazolamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 16/20 | 1.00 |
| ▸ | CA2 known ✓ | P00918 | 16/20 | 1.00 |
| ▸ | CA4 known ✓ | P22748 | 9/20 | 1.00 |
| ▸ | CA12 known ✓ | O43570 | 4/20 | 1.00 |
| ▸ | CA9 | Q16790 | 10/20 | 1.00 |
| ▸ | CA3 | P07451 | 4/20 | 1.00 |
| ▸ | CA6 | P23280 | 4/20 | 1.00 |
| ▸ | CA5A | P35218 | 4/20 | 1.00 |
| ▸ | CA7 | P43166 | 4/20 | 1.00 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CA11 | O75493 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetazolamide SCHEMBL2557036 | 1.00 | CA1 (1.00) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL15513954 | 0.98 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL11301585 | 0.98 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL2845106 | 0.98 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL30094028 | 0.98 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL1998362 | 0.98 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL28346552 | 0.98 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL40812 | 0.98 | CA1 (0.97) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL20553201 | 0.97 | CA1 (0.93) | CA1CA2CA9CA4CA12 | |
| Acetazolamide SCHEMBL9390276 | 0.97 | CA1 (0.93) | CA1CA2CA9CA4CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 31481 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747611-A1 | OPTICAL ELECTRODE ANALYTE DETECTION SYSTEM AND METHODS OF USE | Vital Biosciences Inc. (CA) | 2026-05-27 | — | — | EP | claimed |
| US-12636295-B2 | Compositions and methods for the treatment of obstructive sleep apnoea (OSA) | Incannex Healthcare Limited (AU) | 2026-05-26 | — | — | US | claimed |
| CN-122075467-A | Application of medicine in preventing or treating hydrocephalus | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137654-A1 | COMPOUNDS AND METHODS FOR TREATING AN EPILEPTIC DISORDER | THE REGENTS OF THE UNIV OF CALIFORNIA (US) | 2026-05-21 | — | — | US | claimed |
| US-12630599-B2 | CA2 compositions and methods for tunable regulation | OBSIDIAN THERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | claimed |
| EP-4739302-A2 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | Cella Therapeutics, LLC (US) | 2026-05-13 | — | — | EP | claimed |
| US-20260115289-A1 | LOW DOSE LYMPHODEPLETION WITH ADOPTIVE CELL THERAPY | OBSIDIAN THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | US | claimed |
| US-12605367-B2 | Methods of treatment and/or prevention of disorders and symptoms related to BKCa and/or SK channelophathies | Universite de Bordeaux (FR) | 2026-04-21 | — | — | US | claimed |
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724839-A2 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS | Mediprint Ophthalmics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-4134792-A | Specific binding assay with an enzyme modulator as a labeling substance | MILES LABORATORIES, INC. (US) | 1979-01-16 | — | — | US | claimed |
| US-4132753-A | Process for preparing oral sustained release granules | AMERICAN CYANAMID COMPANY (US) | 1979-01-02 | — | — | US | claimed |
| US-4072575-A | PARA-COUMARIC ACID, ACETAZOLAMIDE | MCDONNELL DOUGLAS CORPORATION (US) | 1978-02-07 | — | — | US | claimed |
| US-4036227-A | Osmotic releasing device having a plurality of release rate patterns | ALZA CORPORATION (US) | 1977-07-19 | — | — | US | claimed |
| US-4036228-A | Osmotic dispenser with gas generating means | ALZA CORPORATION (US) | 1977-07-19 | — | — | US | claimed |
| US-4014334-A | Laminated osmotic system for dispensing beneficial agent | ALZA CORPORATION (US) | 1977-03-29 | — | — | US | claimed |
| US-4008719-A | Osmotic system having laminar arrangement for programming delivery of active agent | ALZA CORPORATION (US) | 1977-02-22 | — | — | US | claimed |
| US-3985892-A | CREAMS | JOUVEINAL S.A. (FR) | 1976-10-12 | — | — | US | claimed |
| US-3977404-A | OSMOTIC DEVICE HAVING MICROPOROUS RESERVOIR | ALZA CORPORATION (US) | 1976-08-31 | — | — | US | claimed |
| US-3934016-A | ACETAZOLAMIDE, POLYOXYETHYLENE GLYCOL | JOUVEINAL, S.A. (FR) | 1976-01-20 | — | — | US | claimed |